Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

Ann Intern Med. 2018 Mar 6;168(5):376-379. doi: 10.7326/M17-2485. Epub 2017 Nov 28.

Authors

Michael D Shapiro¹, Joshua Miles¹, Hagai Tavori¹, Sergio Fazio¹

Affiliation

¹ Oregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.).

PMID: 29181527
DOI: 10.7326/M17-2485

No abstract available

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents / therapeutic use*
Cardiovascular Diseases / drug therapy*
Drug Resistance*
Enzyme-Linked Immunosorbent Assay
Female
Humans
Hyperlipoproteinemia Type II / drug therapy*
Male
Middle Aged
Proprotein Convertase 9 / blood*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
PCSK9 protein, human
Proprotein Convertase 9
evolocumab
alirocumab